Methods The changes of B7 molecule and OX40 and CD11a in peripheral blood white cells an d CD28 in lymphocytes were detected by flow cytometry preoperatively and 3, 5, 7 , 14 days postoperatively in rat cardiac allograft recipients.
One patient was transferred to successful heart transplantation.
In patients with NYHA class IV heart failure and contraindications for heart transplantation, implantation of a long-lasting system is an alternative approach, even though available systems do not yet last forever.
Heart transplantation and implantation of a ventricular assist device (VAD) are complex interventions with a specific range of problems typically arising during intensive care treatment.
Heart transplantation is in our opinion a reconsiderable alternative in the treatment of complex cardiac disease and cardiomyopathy in infants.
Prostaglandin E1 bridge to heart transplantation - methods, technique, results
The assessment of post-transcriptional modifications of VEGF-A mRNA was made on specimens taken from the explanted hearts of patients undergoing cardiac transplantation.
Ventricular assist devices can be used in selected patients with refractory shock as a bridge to cardiac transplantation.
We report about a 17 year old male patient with a cardiomyopathy secondary to type IV glycogenosis (Andersens disease) and class II immunoglobulin deficiency who underwent cardiac transplantation.
Transplant-associated coronary artery disease or cardiac allograft vasculopathy in the major complication after cardiac transplantation.
In this brief review, we will discuss the regulation of endothelin in cardiac transplantation and the pathologial role this peptide plays in renal impairment, systemic hypertension, graft rejection and arteriosclerosis after heart transplantation.
While early after HTX acute rejection and infection episodes were judged as clinically important, later on cardiac allograft vasculopathy, malignancy, and renal insufficiency predominate as relevant complications.
Cardiac allograft vasculopathy - problem and model
Cardiac allograft vasculopathy (CAV) is an accelerated form of atherosclerosis induced by immunological endothelial injury with subsequent inflammatory repair responses in a milieu of additional non-immunological risk factors.
Cardiac allograft vasculopathy - a changing perspective
Together, recent clinical and basic studies show that Cardiac allograft vasculopathy (CAV) is multi-factorial and regulated by interacting forces at different stages.